Abstract
Introduction
Chikungunya is one of the most rapidly spreading mosquito-borne viral infections of global concern including Bangladesh, where it is an emerging infection. [1] [2] [3] In 2017, a massive chikungunya outbreak occurred in Dhaka, the capital city of Bangladesh. 4 Generally, chikungunya is a self-limiting disease; but it may have protracted rheumatological courses and occasionally life-threatening complications like cardiomyopathy and encephalopathy may occur. 2, 5, 6 The objectives of the present study were to describe selected socio-demographic, clinical and laboratory characteristics of chikungunya fever from the 2017 Dhaka outbreak of Bangladesh. (12) or immunoglobulin M (IgM) against chikungunya (done by immunochromatographic test (ICT) for chikungunya IgM/ IgG by using commercially available kits manufactured by SD BIOSENSOR, Republic of Korea) (95)] from July 1, 2017 to October 31, 2017. Patients were followed-up clinically or over phone, as required; specially for rheumatological symptoms; whether they have entered in to sub-acute or chronic phase. Patients with incomplete data, disease duration less than 3 weeks since fever onset and patients who were lost to follow-up were excluded.
Methods

Results
During the study period, a total of 107 patients including 61 (57%) male patients were eligible for analysis. Mean age of the study participants was 35.6 (range 19-84) years. Seventy four (69.2%) patients were from Dhaka North City Corporation and 33 (30.8%) patients were from Dhaka South City Corporation. Twenty two (20.6%) patients had diabetes mellitus. Ninety three (86.9%) patients presented with fever and 14 (13.1%) patients presented after febrile periods because of joint pain. Fourteen patients (13.1%) required hospitalization and two patients (1.9%) had chikungunya-dengue coinfection or sequential infection. Base-line characteristics and common co-morbidities are shown in Table I and Table II respectively. Fever, joint pain and rash were common presentations. Lymph adenopathy was also common, specially among non-diabetic patients (Table III) . Complications, chronicity and initial laboratory reports are shown in Table IV, Table V and Table VI respectively. 
Discussion
The first recognized outbreak of chikungunya fever occurred in Tanzania in 1952-53. 7 Since then outbreaks occurred in different regions and countries. In Bangladesh, first outbreak was recorded in 2008; though cases were thought to be imported from neighboring country, India. 8 The 2017 Dhaka outbreak was a massive one, an estimated 18 million people were affected and claimed few deaths. 4, 9, 10 Cases of imported chikungunya from Bangladesh have also been reported in literature. 11 The clinical manifestation of chikungunya fever is like that of other arboviral infections (like dengue) including fever, arthritis/arthralgia and rashes. In countries with endemic dengue infections like Bangladesh, it is important to differentiate clinically between the two; as NSAIDs for pain relief in arthritis of chikungunya may worsen haemorrhagic manifestations of dengue. Presence of retro-orbital pain suggests dengue, while arthritis suggests chikungunya. 3 Chikungunya-dengue co-infections are also to be remembered and such infections have been reported from Bangladesh. 10, [12] [13] [14] [15] Clinical presentation of our cohort was not far different from two different reports from the same 2017 Dhaka outbreak published in literature. 9, 16 Features were comparable with other chikungunya cohorts in literature as well. 17 Lymph adenopathy was common in nondiabetic patients in our series, while neurological and cardiovascular complications were less common. But we found acute kidney injury in one-tenth of our cases. Most chikungunya cases can be managed at home but severe cases require hospitalization and sometimes intensive care. 10, 18 The follow-up period of our cohort was limited. Only one-tenth of patients had passed 3 months since fever onset. One in 11 patients had chronic joint symptoms. Post chikungunya rheumatisms is an established sequel, though percentage varies in different countries. 19, 20 Patients with post chikungunya rheumatism require evaluations and it is not unlikely that an infective episode may unmask chronic rheumatism in genetically predisposed individual. 21 Patients with postchikungunya rheumatism were managed differently and there is a published guidelines for such management by the Brazilian Society of Rheumatology. 22 Diagnosis of chikungunya requires clinical, epidemiological and laboratory criteria. RT-PCR is most reliable but not widely available and costly. IgM or increasing titres of IgG against chikungunya may be used. Care should be taken not to miss dengue. Lifethreating neurological or cardiovascular complications are rare, but need high index of suspicion and aggressive interventions. Like any other vector borne diseases, mosquito control is important intervention in breaking chikungunya transmission. 23 It will benefit against dengue and other mosquito-borne infections as well.
As chikungunya is an emerging infection in Bangladesh and the clinical features are similar to dengue, we urge physicians should be aware of making a diagnosis of chikungunya carefully and exclude dengue with equal emphasis. Concomitant chikungunya and dengue infections are also possible. Improving awareness among general population is equally important; specially for the prevention of disease transmission.
